



03-17-04

Express Mail No: EV 376 296 618 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Chen *et al.* Confirmation No.: 4030
Serial No.: 10/705,173 Art Unit: 1614
Filed: November 6, 2003 Examiner: To be Assigned
For: FUSED HETEROCYCLIC Attorney Docket No.: 11134-013-999
COMPOUNDS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
 - 1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.
 - 1b. A legible copy of :
 - ☒ Each U.S. patent application publication and U.S. and foreign patent;
 - ☒ Each publication or that portion which caused it to be listed on the PTO-1449;
 - ☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
 - ☐ all other information or portion which caused it to be listed on the PTO-1449.
 - 1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
 - 1d. ☒ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
2. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
 - ☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;

- ☒ Before the mailing of the first Office action on the merits;
- ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

3. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
☐ enclosed
☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

The Certification Statement in Item 5 below is applicable.

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked)

(Check either Item 5a or 5b)

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. ☐ In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No., filed on , of which this application claims priority under 35 U.S.C. §120, are being submitted for the U.S. Patent Office's convenience.

- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7. ☐ This is a Supplemental Information Disclosure Statement. (Check Item 7a)
- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
- (Check Item 8a, 8b, or 8c)
- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150.
10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §1.97(g) and (h).

Respectfully submitted,

Date: March 15, 2004


Rahul Pathak

42,983

(Reg. No.)

For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY

222 East 41st Street

New York, New York 10017-6702.

(212) 326-3939

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

11134-013-999

APPLICATION NO

10/705,173

APPLICANT

Chen et al.

FILING DATE

November 6, 2003

GROUP

To be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,115,538	9/19/78	Satoh et al.			
	A02	5,436,128	7/25/95	Harpold et al.			
	A03	5,049,655	9/17/91	Vaughan et al.			
	A04	5,272,146	12/21/93	Haugwitz et al.			
	A05	5,449,766	9/12/95	Vaughan et al.			
	A06	5,530,095	6/25/96	Vaughan et al.			
	A07	5,849,708	12/15/98	Maratos-Flier			
	A08	6,033,872	3/7/00	Bergsma et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A09	EP 0 257 701	8/14/87	EPO				
	A10	WO99/28492	12/2/98	PCT				
	A11	WO99/64002	6/10/99	PCT				
	A12	WO00/15793	9/17/99	PCT				
	A13	WO00/22129	10/12/99	PCT				
	A14	WO00/39279	12/30/99	PCT				
	A15	WO00/40725	12/27/99	PCT				
	A16	WO00/49046	2/18/00	PCT				
	A17	WO00/49170	1/20/00	PCT				
	A18	WO00/70347	11/23/00	PCT				
	A19	WO00/75166	6/6/00	PCT				
	A20	WO01/05947	7/10/00	PCT				
	A21	WO01/07606	7/27/00	PCT				
	A22	WO01/07611	7/21/00	PCT				
	A23	WO01/21577	9/19/00	PCT				
	A24	WO01/36479	11/14/00	PCT				
	A25	WO01/68706	3/14/01	PCT				
	A26	WO01/70975	3/23/01	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A27	Berridge, <i>et al.</i> "Inositol Triphosphate, a Novel Second Messenger In Cellular Signal Transduction", Nature (1984) 312:315-321.
	A28	Chambers, <i>et al.</i> "Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1", Nature (1999) 400: 261-265.
	A29	Felley-Bosco, <i>et al.</i> "Constitutive Expression of Inducible Nitric Oxide Synthase in Human Brochial Epithelial Cells Induces c-fos and Stimulates the cGMP Pathway", Am J. Respir Cell. Mol. Biol. (1994) 11: 159-164.

A30	Gonzalez, <i>et al.</i> , "alpha-Melanocyte-stimulating hormone (alpha-MSH) and melanin-concentrating hormone (MCH) modify monoaminergic levels in the preoptic area of the rat" <i>Peptides</i> (1997) 18:387-392.
A31	Gonzalez, <i>et al.</i> , "Behavioral Effects of α -MSH and MCH After Central Administration in the Female Rat" <i>Peptides</i> (1996) 17(1):171-177.
A32	Monzon, <i>et al.</i> , "Response to Novelty After I.C.V. Injection of Melanin-Concentrating Hormone (MCH) in Rats" <i>Physiol. Behav.</i> (1999) 67(5):813-817.
A33	Offerman, <i>et al.</i> , " $G\alpha_{15}$ and $G\alpha_{16}$ Couple A Wide Variety of Receptors to Phospholipase C", <i>The J. of Biological chemistry</i> (1995), 270(25) pgs. 15175-15180.
A34	Rai, <i>et al.</i> , "Synthesis, Physicochemical Properties, and Evaluation of N-Substituted-2-Alkyl-3-Hydroxy-4(1H)-Pyridones" <i>J. Med. Chem.</i> (1998) 41:3347-3359.
A35	Saito, <i>et al.</i> , "Molecular characterization of the melanin-concentrating-hormone receptor", <i>Nature</i> (1999) 400: 265-269.
A36	Saito, <i>et al.</i> , "Melanin-concentrating hormone receptor: an orphan receptor fits the key" <i>Trends Endocrinol. Metab.</i> (2000) 11(8): 299-303.
A37	Seyferth, <i>et al.</i> , "Some Reactions of Dimethylphosphono-Substituted Diazoalkanes. $(MeO)_2P(O)CR$ Transfer to Olefins and 1,3-Dipolar Additions of $(MeO)_2P(O)C(N_2)R^1$ ", <i>J. Org. Chem.</i> (1971) 36(10): 1379-1386.
A38	Shimada, <i>et al.</i> , "Mice Lacking melanin-concentrating hormone are Hypophagic and Lean", <i>Nature</i> (1998) 396: 670-674.
A39	Wilkie, <i>et al.</i> , "Characterization of G-Protein α Subunits in the G_q Class: Expression in Murine Tissues and In Stromal and Hematopoietic Cell Lines", <i>Proc. Natl. Acad. Sci. USA</i> (1991) 88: pgs 10049-10053..

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

11134-013-999

APPLICATION NO

10/705,173

APPLICANT

Chen et al.

FILING DATE

November 6, 2003

GROUP

To be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,115,538	9/19/78	Satoh et al.			
	A02	5,436,128	7/25/95	Harpold et al.			
	A03	5,049,655	9/17/91	Vaughan et al.			
	A04	5,272,146	12/21/93	Haugwitz et al.			
	A05	5,449,766	9/12/95	Vaughan et al.			
	A06	5,530,095	6/25/96	Vaughan et al.			
	A07	5,849,708	12/15/98	Maratos-Flier			
	A08	6,033,872	3/7/00	Bergsma et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A09	EP 0 257 701	8/14/87	EPO				
	A10	WO99/28492	12/2/98	PCT				
	A11	WO99/64002	6/10/99	PCT				
	A12	WO00/15793	9/17/99	PCT				
	A13	WO00/22129	10/12/99	PCT				
	A14	WO00/39279	12/30/99	PCT				
	A15	WO00/40725	12/27/99	PCT				
	A16	WO00/49046	2/18/00	PCT				
	A17	WO00/49170	1/20/00	PCT				
	A18	WO00/70347	11/23/00	PCT				
	A19	WO00/75166	6/6/00	PCT				
	A20	WO01/05947	7/10/00	PCT				
	A21	WO01/07606	7/27/00	PCT				
	A22	WO01/07611	7/21/00	PCT				
	A23	WO01/21577	9/19/00	PCT				
	A24	WO01/36479	11/14/00	PCT				
	A25	WO01/68706	3/14/01	PCT				
	A26	WO01/70975	3/23/01	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A27	Berridge, <i>et al.</i> "Inositol Triphosphate, a Novel Second Messenger In Cellular Signal Transduction", Nature (1984) 312:315-321.
	A28	Chambers, <i>et al.</i> "Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1", Nature (1999) 400: 261-265.
	A29	Felley-Bosco, <i>et al.</i> "Constitutive Expression of Inducible Nitric Oxide Synthase in Human Brochial Epithelial Cells Induces c-fos and Stimulates the cGMP Pathway", Am J. Respir Cell. Mol. Biol. (1994) 11: 159-164.

A30	Gonzalez, <i>et al.</i> , "alpha-Melanocyte-stimulating hormone (alpha-MSH) and melanin-concentrating hormone (MCH) modify monoaminergic levels in the preoptic area of the rat" <i>Peptides</i> (1997) 18:387-392.
A31	Gonzalez, <i>et al.</i> , "Behavioral Effects of α -MSH and MCH After Central Administration in the Female Rat" <i>Peptides</i> (1996) 17(1):171-177.
A32	Monzon, <i>et al.</i> , "Response to Novelty After I.C.V. Injection of Melanin-Concentrating Hormone (MCH) in Rats" <i>Physiol. Behav.</i> (1999) 67(5):813-817.
A33	Offerman, <i>et al.</i> , " $G\alpha_{i5}$ and $G\alpha_{i6}$ Couple A Wide Variety of Receptors to Phospholipase C", <i>The J. of Biological Chemistry</i> (1995), 270(25) pgs. 15175-15180.
A34	Rai, <i>et al.</i> , "Synthesis, Physicochemical Properties, and Evaluation of N-Substituted-2-Alkyl-3-Hydroxy-4(1H)-Pyridones" <i>J. Med. Chem.</i> (1998) 41:3347-3359.
A35	Saito, <i>et al.</i> , "Molecular characterization of the melanin-concentrating-hormone receptor", <i>Nature</i> (1999) 400: 265-269.
A36	Saito, <i>et al.</i> , "Melanin-concentrating hormone receptor: an orphan receptor fits the key" <i>Trends Endocrinol. Metab.</i> (2000) 11(8): 299-303.
A37	Seyferth, <i>et al.</i> , "Some Reactions of Dimethylphosphono-Substituted Diazoalkanes. $(MeO)_2P(O)CR$ Transfer to Olefins and 1,3-Dipolar Additions of $(MeO)_2P(O)C(N_2)R^1$ ", <i>J. Org. Chem.</i> (1971) 36(10): 1379-1386.
A38	Shimada, <i>et al.</i> , "Mice Lacking melanin-concentrating hormone are Hypophagic and Lean", <i>Nature</i> (1998) 396: 670-674.
A39	Wilkie, <i>et al.</i> , "Characterization of G-Protein α Subunits in the G_q Class: Expression in Murine Tissues and In Stromal and Hematopoietic Cell Lines", <i>Proc. Natl. Acad. Sci. USA</i> (1991) 88: pgs 10049-10053..

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.